ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Rare disease drug development
Will Maier outlines the importance of utilising real world evidence from rare diseases in accelerating product approval and development.
CAR-T cell therapy in oncology
Cell and gene therapies in oncology are bringing new options to patients.
Application of project management strategy to postapproval CMC submissions
Application of project management strategy to postapproval CMC submissions.
The Use of Predictive Analytics to Improve Quality in Clinical Trials Quality Assurance
Rose Kidd, Executive Vice President, Quality and Compliance at ICON, discusses how predictive analytics provide a real opportunity to develop new and innovative processes in the area of QA.
Providing support throughout the patient journey
Laney Preheim outlines how the concierge services can be best implemented to improve patient journey in a decentralised clinical trial.
Anthrax vaccine clinical trial
This news article, first published on Contract Pharma.com, outlines how ICON has been selected by BARDA to execute an anthrax vaccine clinical trial.
Using RWE in rare disease drug development: effective innovations with historical controls
With a growing number of therapies under development for rare diseases, William Maier discusses how real-world evidence can be effectively used as a historical control, overcoming challenges presented in clinical development.
Robotic Process Automation: Recruiting bots to accelerate clinical trials
Robotics software can streamline error-prone clinical trial processes, bringing patient and employee value.
Redefining CRO sourcing model terminology to optimise outsourcing strategies
Differentiating FSO and FSP approaches can better align definitions of models for CROs and sponsors.
Embedding the patient point of view in everything you do
Rachel Ballinger, Patient Centred Outcomes Principal, shares the importance of using positive language when speaking with study participants.